Cargando…

Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer

Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastati...

Descripción completa

Detalles Bibliográficos
Autores principales: El Hejjioui, Brahim, Bouguenouch, Laila, Melhouf, Moulay Abdelilah, El Mouhi, Hind, Bennis, Sanae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914403/
https://www.ncbi.nlm.nih.gov/pubmed/36766575
http://dx.doi.org/10.3390/diagnostics13030470
_version_ 1784885661190324224
author El Hejjioui, Brahim
Bouguenouch, Laila
Melhouf, Moulay Abdelilah
El Mouhi, Hind
Bennis, Sanae
author_facet El Hejjioui, Brahim
Bouguenouch, Laila
Melhouf, Moulay Abdelilah
El Mouhi, Hind
Bennis, Sanae
author_sort El Hejjioui, Brahim
collection PubMed
description Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastatic breast cancer, approximately 6% to 10% of new breast cancer cases are initially staged IV (de novo metastatic disease). The number of metastatic recurrences is estimated to be 20–30% of all existing breast tumor cases, whereby the need to develop specific genetic markers to improve the prognosis of patients suffering from these deadly forms of breast cancer. As an alternative, liquid biopsy methods can minutely identify the molecular architecture of breast cancer, including aggressive forms, which provides new perspectives for more precise diagnosis and more effective therapeutics. This review aimed to summarize the current clinical evidence for the application of circulating tumor DNA in managing breast cancer by detailing the increased usefulness of this biomarker as a diagnostic, prognostic, monitoring, and surveillance marker for breast cancer.
format Online
Article
Text
id pubmed-9914403
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99144032023-02-11 Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer El Hejjioui, Brahim Bouguenouch, Laila Melhouf, Moulay Abdelilah El Mouhi, Hind Bennis, Sanae Diagnostics (Basel) Review Breast cancer is clinically and biologically heterogeneous and is classified into different subtypes according to the molecular landscape of the tumor. Triple-negative breast cancer is a subtype associated with higher tumor aggressiveness, poor prognosis, and poor response to treatment. In metastatic breast cancer, approximately 6% to 10% of new breast cancer cases are initially staged IV (de novo metastatic disease). The number of metastatic recurrences is estimated to be 20–30% of all existing breast tumor cases, whereby the need to develop specific genetic markers to improve the prognosis of patients suffering from these deadly forms of breast cancer. As an alternative, liquid biopsy methods can minutely identify the molecular architecture of breast cancer, including aggressive forms, which provides new perspectives for more precise diagnosis and more effective therapeutics. This review aimed to summarize the current clinical evidence for the application of circulating tumor DNA in managing breast cancer by detailing the increased usefulness of this biomarker as a diagnostic, prognostic, monitoring, and surveillance marker for breast cancer. MDPI 2023-01-27 /pmc/articles/PMC9914403/ /pubmed/36766575 http://dx.doi.org/10.3390/diagnostics13030470 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
El Hejjioui, Brahim
Bouguenouch, Laila
Melhouf, Moulay Abdelilah
El Mouhi, Hind
Bennis, Sanae
Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
title Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
title_full Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
title_fullStr Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
title_full_unstemmed Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
title_short Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer
title_sort clinical evidence of circulating tumor dna application in aggressive breast cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9914403/
https://www.ncbi.nlm.nih.gov/pubmed/36766575
http://dx.doi.org/10.3390/diagnostics13030470
work_keys_str_mv AT elhejjiouibrahim clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer
AT bouguenouchlaila clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer
AT melhoufmoulayabdelilah clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer
AT elmouhihind clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer
AT bennissanae clinicalevidenceofcirculatingtumordnaapplicationinaggressivebreastcancer